aBLA Filing Intelligence & Biosimilar Opportunity

Bimzelx

Bimekizumab

Immunomodulators

Injection

Bimzelx is a subcutaneous injection used to treat plaque psoriasis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis), and hidradenitis suppurativa. It targets and blocks IL‑17A and IL‑17F cytokines to reduce inflammation and skin/joint symptoms.

Approval Date

17-Oct-23

Data Exclusivity Expiry

17-Oct-27

Market Exclusivity Expiry

17-Oct-35

Commercial snapshot

Market performance & projections

Revenue ($M)

2,513

CAGR (%)

27.25%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

3,581

2027

4,699

2028

5,723

2029

6,589

2030

7,330

2031

7,960

2032

8,384

Molecule profile

Details & specifications

Molecule

Bimekizumab

Innovator

UCB INC

Dosage Form

Injection

Strength

160 mg/mL

Therapeutic Category

Immunomodulators

Usage

To treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets